I n the fall of 2015, the United States joined the growing list of countries in which trabectedin, a novel form of chemotherapy, is approved for the treatment of certain types of advanced soft tissue sarcoma. Te drug, a synthetic derivative of a compound originally isolated from a sea squirt, has a complex mechanism of action that distinguishes it from other cytotoxic drugs, allowing it to target both the tumor and its microenvironment.
Based on the results of a randomized, open-label, multicenter phase 3 clinical trial, trabectedin received regulatory approval for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma. Tese represent 2 of the most common types of sarcoma occurring in the fat cells and smooth muscle cells, respectively, and patients have few efective therapeutic options. Trabectedin is approved for use in patients who previously received anthracyclinebased chemotherapy.
Te ET743-SAR-3007 trial enrolled patients at 85 sites in 4 diferent countries from May 27, 2011 to September 16, 2013. Patients were aged 15 years or older, with unresectable, locally advanced or metastatic liposarcoma or leiomyosarcoma, had been previously treated with either a combination of an anthracycline and ifosfamide or an anthracycline plus 1 or more additional cytotoxic chemotherapy regimens. Eligible patients were also required to have adequate bone marrow, renal and liver functions, and an Eastern Cooperative Oncology Group performance status of 1 or lower. Tose with known central nervous system metastases, myocardial infarction within the 6 months before enrollment, or New York Heart Association class II or greater heart failure were excluded from the study.
In all, 518 patients were randomly assigned in a 2:1 ratio to receive either trabectedin at a starting dose of 1.5 mg/ m 2 or dacarbazine at a starting dose of 1 g/m 2 . Te study drug was administered on day 1 of each 21-day treatment cycle until disease progression or unacceptable toxicity. Trabectedin was administered over 24 hours as an intravenous infusion, following premedication with intravenous dexamethasone 20 mg, and dacarbazine was administered as a 20-120-minute intravenous infusion.
Tumor response was assessed by radiographic imaging of the chest, abdomen, and pelvis every 6 weeks for the frst 36 weeks and then every 9 weeks thereafter until disease progression, subsequent anticancer therapy, or patient death occurred. Te primary endpoint was overall survival (OS), with secondary endpoints of progression-free survival (PFS), time to progression, objective response rate (ORR), and duration of response.
Baseline demographics and disease characteristics were well balanced. Te patients had been heavily pretreatedmore than 80% had received at least 2 prior lines of systemic therapy, more than 90% had previous surgery, and half had prior radiation therapy.
After 329 PFS events, median PFS was signifcantly Community Translations improved in the trabectedin group (4.2 vs 1.5 months in the dacarbazine arm) and trabectedin treatment resulted in a 45% reduction in the risk of disease progression or death. PFS beneft was observed across all preplanned subgroups and in both sarcoma subtypes and was confrmed by an independent review of radiographic PFS. Subsequent anticancer therapy was used less in the trabectedin group and median time to initiation of this therapy was also signifcantly longer. ORR was also signifcantly higher in trabectedin-treated patients (9.9% vs 6.9%) and, although there were no complete responses in either group, trabectedin resulted in more partial responses and stable disease as best response. Median duration of response was 6.5 months in the trabectedin arm, compared with 4.2 months in the dacarbazine arm, and median duration of stable disease was also longer with trabectedin treatment. Te clinical beneft rate was 34% compared with 19% in the 2 arms.
Although no signifcant improvement in OS was observed, the OS results favored the trabectedin arm, with an overall 13% reduction in the risk of death. OS results may have been confounded by post-trial chemotherapy and median OS in the dacarbazine group, which was reported to exceed historical expectations.
Te adverse event (AE) profle of both drugs was consistent with previously reported safety and toxicity profles, most commonly grade 1-2 in severity. Te most common AEs experienced in the trabectedin arm included nausea, fatigue, vomiting, diarrhea, constipation, decreased appetite, dyspnea, headache, peripheral edema, neutropenia, thrombocytopenia, anemia, elevated liver enzymes, and decreased albumin levels. Te proportion of patients 
Mechanism of action: trabectedin
The marine-derived drug trabectedin is thought to have a multi-faceted mechanism of action that distinguishes it from other cytotoxic agents. In addition to direct effects on the tumor, it also affects normal host cells in the tumor microenvironment, such as monocytes and tumor-associated macrophages. who died within 60 days of the frst dose was similar in the 2 treatment arms (7.1% and 5.8% for trabectedin and dacarbazine, respectively), though treatment-related deaths occurred only in the trabectedin arm.
Te recommended dose of trabectedin is 1.5 mg/m 2 administered over 24 hours through a central venous line every 21 days in patients with normal bilirubin and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels ≤2.5 times the upper limit of normal (ULN). Trabectedin carries a boxed warning, alerting health care practitioners to the risk of severe and fatal blood infections, rhabdomyolysis, hepatotoxicity, extravasation, tissue necrosis, and heart failure and cautions medical practitioners to advise women of the potential risk to a developing fetus and not to breastfeed while taking the drug.
Trabectedin is marketed as Yondelis by Janssen Pharmaceuticals Inc. Te prescribing information advises that neutrophil count, creatinine phosphokinase levels, and liver function tests (defned as ALT, AST, total bilirubin, and alkaline phosphatase levels) should be assessed before each dose of trabectedin, and left ventricular ejection fraction (LVEF) should be assessed before starting on this drug and at 2-3 month intervals thereafter. Trabectedin treatment should be withheld for neutrophil counts <1,500 cells/µL on the day of dosing, serum CPK levels >2.5 times ULN, and LVEF below the lower limit of normal.
Elevated liver function tests should be managed with treatment interruption, dose reduction, or permanent discontinuation refecting the severity and duration. Trabectedin should be discontinued in the event of lifethreatening or prolonged, severe neutropenia in the previous cycle, for rhabdomyolysis, and for symptomatic cardiomyopathy or persistent left ventricular dysfunction that doesn't recover to the lower limit of normal within 3 weeks.
